Patents by Inventor William R. Majarian

William R. Majarian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant flagellin vaccines
    Patent number: 6130082
    Abstract: The present invention is directed to recombinant genes and their encoded proteins which are recombinant flagellin fusion proteins. Such fusion proteins comprise amino acid sequences specifying an epitope encoded by a flagellin structural gene and an epitope of a heterologous organism which is immunogenic upon introduction of the fusion protein into a vertebrate host. The recombinant genes and proteins of the present invention can be used in vaccine formulations, to provide protection against infection by the heterologous organism, or to provide protection against conditions or disorders caused by an antigen of the organism. In a specific embodiment, attenuated invasive bacteria expressing the recombinant flagellin genes of the invention can be used in live vaccine formulations. The invention is illustrated by way of examples in which epitopes of malaria circumsporozoite antigens, the B subunit of Cholera toxin, surface and presurface antigens of Hepatitis B.
    Type: Grant
    Filed: February 14, 1992
    Date of Patent: October 10, 2000
    Assignees: American Cyanamid Company, The Board of Trustees of the Leland Stanford Junior University
    Inventors: William R. Majarian, Bruce A. D. Stocker, Salete M. C. Newton
  • Method for detection of non-denatured nucleic acid fragments
    Patent number: 6037127
    Abstract: A method for detecting the presence of a nucleic acid analyte in a test sample is provided in which a test sample is contacted with a test strip of a chromatographic bibulous porous material which is capable of moving the test sample laterally along the test strip by capillary migration to ultimate capture by a moiety in a specific capture zone.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: March 14, 2000
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Richard C. Ebersole, Edwin R. Hendrickson, Mark S. Payne, Sandra Fitzpatrick-McElligott, William R. Majarian, Jan A. Rafalski
  • Vaccines for the malaria circumsporozoite protein
    Patent number: 5112749
    Abstract: The present invention is directed to attenuated strains of enteroinvasive bacteria that express a peptide or protein related to an epitope of the malaria parasites of the genus Plasmodium. The bacterial strains of the invention which can multiply in a host without causing significant disease or disorder, and which express a Plasmodium-related peptide that induces a protective immune response against malaria, can be used in live vaccine formulations for malaria. In specific embodiments, a Plasmodium-related peptide can be expressed as a fusion protein, for example, with a bacterial enterotoxin.The invention also relates to methods for expression of malaria antigens or fragments thereof within attenuated enteroinvasive bacteria.In particular embodiments, the invention is directed to the expression by attenuated Salmonella spp. of epitopes of Plasmodium circumsporozoite proteins.
    Type: Grant
    Filed: October 2, 1987
    Date of Patent: May 12, 1992
    Assignee: Praxis Biologics, Inc.
    Inventors: Robert N. Brey, III, William R. Majarian, Subramonia Pillai, Wayne T. Hockmeyer